Clinical Trial

Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy

Recruiting
View on ClinicalTrials.gov →
Summary
Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression
Trial Details
NCT Number NCT07327905
Lead Sponsor Alexandria University
Conditions Bariatric Surgery, Lidocaine, Dexmedetomidine
Enrollment 40 participants
Start Date 2025-12-26
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-08